Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 7/20 | 0.46 |
| ▸ | MELK | Q14680 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.46 |
| ▸ | EGFR | P00533 | 9/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | BCL6B | Q8N143 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30798264 | 1.00 | BCL6 (0.46) | BCL6MELKNCOR2EGFRERBB2 | |
| SCHEMBL30894407 | 1.00 | BCL6 (0.46) | BCL6MELKNCOR2EGFRERBB2 | |
| SCHEMBL24717551 | 0.98 | BCL6 (0.46) | BCL6MELKNCOR2EGFRERBB2 | |
| SCHEMBL30894100 | 0.98 | BCL6 (0.46) | BCL6MELKNCOR2EGFRERBB2 | |
| SCHEMBL30894364 | 0.98 | BCL6 (0.46) | BCL6MELKNCOR2EGFRERBB2 | |
| SCHEMBL24718765 | 0.98 | BCL6 (0.46) | BCL6MELKNCOR2EGFRERBB2 | |
| SCHEMBL24717915 | 0.97 | BCL6 (0.45) | BCL6MELKNCOR2EGFRERBB2 | |
| SCHEMBL30894135 | 0.97 | BCL6 (0.45) | BCL6MELKNCOR2EGFRERBB2 | |
| SCHEMBL27220372 | 0.97 | BCL6 (0.45) | BCL6MELKNCOR2EGFRERBB2 | |
| SCHEMBL24718779 | 0.97 | BCL6 (0.47) | BCL6MELKNCOR2EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151557-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11986532-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986532-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | BCL6 1/4885MELK 619/4885NCOR2 620/4885 |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | BCL6 1/4885MELK 619/4885NCOR2 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.